Physician profile
Harold A Bernstein
NPI 1215921994
$6,796.20
in general payments reported to CMS, 2019-2025
23 companies · $1,477 in 2025
The $1,477 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $613 · 2020: $1,603 · 2021: $474 · 2022: $824 · 2023: $644 · 2024: $1,161 · 2025: $1,477.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,281.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $1,260.99 | 2019-2021 | |
| Alcon Vision LLC | $1,253.21 | 2019-2025 | Clareon, Hydrus Microstent, Clareon Panoptix Pro |
| Glaukos Corporation | $841.82 | 2021-2025 | Idose, Istent Infinite |
| Abbvie INC. | $763.44 | 2022-2025 | Xen Glaucoma Treatment System |
| New World Medical,INC. | $737.43 | 2020-2025 | Ahmed Glaucoma Valve, Kahook Dual Blade, Via360 |
| Allergan, INC. | $470.05 | 2020-2022 | |
| Sight Sciences, INC. | $243.56 | 2019-2024 | Omni Surgical System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $230.77 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $217.03 | 2019-2023 | Cequa |
| Bausch & Lomb Americas INC. | $153.05 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Ocular Therapeutix, INC. | $150.02 | 2020 | |
| Mallinckrodt Hospital Products INC. | $124.34 | 2020 | |
| Novartis Pharmaceuticals Corporation | $61.18 | 2019-2020 | |
| Mallinckrodt Enterprises LLC | $48.18 | 2019 | |
| Rayner Intraocular Lenses Limited | $46.14 | 2023-2025 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $41.18 | 2019-2021 | |
| Omeros Corporation | $30.32 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $28.51 | 2023 | Artevo 800 |
| Oyster Point Pharma, INC. | $22.65 | 2023 | Tyrvaya |
| Horizon Therapeutics Plc | $20.64 | 2023 | Tepezza |
| Thea Pharma INC. | $19.81 | 2023 | Iyuzeh |
| Eyevance Pharmaceuticals LLC | $17.94 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $13.94 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Bernstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.